[Current antiplatelet agents, new inhibitors and therapeutic targets].
Antiplaquettaires actuels, en cours de développement et cibles thérapeutiques.
Aspirin
/ therapeutic use
Blood Coagulation
/ drug effects
Blood Platelets
/ drug effects
Cardiovascular Diseases
/ drug therapy
Hemorrhage
/ chemically induced
Humans
Molecular Targeted Therapy
/ methods
Platelet Aggregation Inhibitors
/ therapeutic use
Platelet Glycoprotein GPIIb-IIIa Complex
/ antagonists & inhibitors
Risk Factors
Therapies, Investigational
/ methods
Journal
Medecine sciences : M/S
ISSN: 1958-5381
Titre abrégé: Med Sci (Paris)
Pays: France
ID NLM: 8710980
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
entrez:
2
5
2020
pubmed:
2
5
2020
medline:
2
10
2020
Statut:
ppublish
Résumé
Cardiovascular diseases are the leading cause of deaths in the world. Platelets play a major role in the occurrence of these diseases and the development of antiplatelet drugs is a priority in the fight against cardiovascular diseases-associated mortality. Aspirin and thienopyridine-based P2Y12 inhibitors are the main drugs currently used. These molecules target the initiation of platelets activation and are responsible for a moderate inhibitory action. Other antiplatelet agents, as glycoprotein (GP) IIb/IIIa antagonists, inhibit platelet aggregation independently of initial activation-associated pathways, but are responsible for increased hemorrhagic events. Regarding each antiplatelet agent's specific characteristics, the prescription of these drugs must take into account the type of cardiovascular event, the age of the patient, the past medical history, and the potential hemorrhagic adverse events. Thus, there is a need for the development of new molecules with a more targeted effect, maintaining optimal efficiency but with a reduction of the hemorrhagic risk, which is the principal limitation of these treatments. Antiplaquettaires actuels, en cours de développement et cibles thérapeutiques. Les maladies cardiovasculaires (MCV) sont la première cause de mortalité dans le monde. Les plaquettes jouent un rôle majeur dans le développement de ces maladies et la mise au point d’antiplaquettaires efficaces constitue une priorité dans le cadre de la lutte contre la mortalité liée aux MCV. L’aspirine et les médicaments de la famille des thiénopyridines sont les agents antiplaquettaires les plus utilisés actuellement. Ces médicaments ciblent des voies de signalisation impliquées dans l’initiation de l’agrégation, exerçant ainsi un effet antiplaquettaire modéré. D’autres médicaments aux effets plus importants, comme les molécules dirigées contre le récepteur GPIIb/IIIa, inhibent l’agrégation plaquettaire indépendamment de la voie de signalisation initiant l’activation plaquettaire, mais ils sont associés à des complications hémorragiques majorées. Étant données les caractéristiques spécifiques de chacun de ces agents antiplaquettaires, leur prescription nécessite de prendre en compte le type d’évènement cardio-vasculaire, l’âge et les comorbidités du patient traité et, bien sûr, les effets secondaires hémorragiques potentiels de la molécule qui est prescrite. Apparaît donc la nécessité de mettre au point de nouvelles molécules ayant un effet plus ciblé, gardant une efficacité optimale, mais permettant une réduction du risque hémorragique qui constitue la principale limite des médicaments antiplaquettaires.
Autres résumés
Type: Publisher
(fre)
Antiplaquettaires actuels, en cours de développement et cibles thérapeutiques.
Identifiants
pubmed: 32356711
doi: 10.1051/medsci/2020061
pii: msc190260
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Platelet Glycoprotein GPIIb-IIIa Complex
0
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
348-357Informations de copyright
© 2020 médecine/sciences – Inserm.
Références
Maurer E , Tang C , Schaff M et al. Targeting platelet GPIbβ reduces platelet adhesion, GPIb signaling and thrombin generation and prevents arterial thrombosis. Arterioscler Thromb Vasc Biol 2013 ; 33 : 1221–1229.
Manne BK , Badolia R , Dangelmaier C et al. Distinct pathways regulate Syk protein activation downstream of immune tyrosine activation motif (ITAM) and hemITAM receptors in platelets. J Biol Chem 2015 ; 290 : 11557–11568.
Onselaer MB , Hardy AT , Wilson C et al. Fibrin and D-dimer bind to monomeric GPVI. Blood Adv 2017 ; 1 : 1495–1504.
Badimon L , Padró T , Vilahur G . Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease. Eur Heart J Acute Cardiovasc Care 2012 ; 1 : 60–74.
Stefanini L , Bergmeier W . RAP1-GTPase signaling and platelet function. J Mol Med 2016 ; 94 : 13–19.
Flevaris P , Li Z , Zhang G et al. Two distinct roles of mitogen-activated protein kinases in platelets and a novel Rac1-MAPK-dependent integrin outside-in retractile signaling pathway. Blood 2009 ; 113 : 893–901.
Valet C , Severin S , Chicanne G et al. The role of class I, II and III PI 3-kinases in platelet production and activation and their implication in thrombosis. Adv Biol Regul 2016 ; 61 : 33–41.
Ricciotti E , FitzGerald GA . Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011 ; 31 : 986–1000.
Verdoia M , Schaffer A , Barbieri L et al. Benefits from nnew ADP antagonists as compared with clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: a meta-analysis of randomized trials. J Cardiovasc Pharmaco 2014 ; 63 : 339–350.
Teng R , Butler K . Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 2010 ; 66 : 487–496.
Roffi M , Patrono C , Collet JP et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European society of cardiology (ESC). Eur Heart J 2016 ; 37 : 267–315.
Angiolillo DJ . ADP receptor antagonism: what’s in the pipeline?. Am J Cardiovasc Drugs Drugs Devices Interv 2007 ; 7 : 423–432.
Boldron C , Besse A , Bordes MF et al. N-[6-(4-butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a novel intravenous and oral, reversible, and directly acting P2Y12 antagonist. J Med Chem 2014 ; 57 : 7293–7316.
Coller BS . αIIbβ3: structure and function. J Thromb Haemost 2015 ; 13 : suppl 1 S17–S25.
Shah I , Khan SO , Malhotra S et al. Eptifibatide: the evidence for its role in the management of acute coronary syndromes. Core Evid 2009 ; 4 : 49–65.
Jeong YH , Tantry US , Park Y et al. Pharmacodynamic effect of cilostazol plus standard clopidogrel versus double-dose clopidogrel in patients with type 2 diabetes undergoing percutaneous coronary intervention. Diabetes Care 2012 ; 35 : 2194–2197.
Ozat M , Gungor T , Barun S et al. The effects of iloprost, a prostacyclin analogue, in experimental ischaemia/reperfusion injury in rat ovaries. Exp Toxicol Pathol 2009 ; 61 : 519–527.
Han X , Nieman MT . PAR4 (protease-activated receptor 4): particularly important 4 antiplatelet therapy. Arterioscler Thromb Vasc Biol 2018 ; 38 : 287–289.
Zhang HC , Derian CK , Andrade-Gordon P et al. Discovery and optimization of a novel series of thrombin receptor (par-1) antagonists: potent, selective peptide mimetics based on indole and indazole templates. J Med Chem 2001 ; 44 : 1021–1024.
Damiano BP , Derian CK , Maryanoff BE et al. RWJ-58259: a selective antagonist of protease activated receptor-1. Cardiovasc Drug Rev 2003 ; 21 : 313–326.
Robinson E , Knight E , Smoktunowicz N et al. Identification of an active metabolite of PAR-1 antagonist RWJ-58259 and synthesis of analogues to enhance its metabolic stability. Org Biomol Chem 2016 ; 14 : 3198–3201.
Morrow DA , Braunwald E , Bonaca MP et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012 ; 366 : 1404–1413.
Tricoci P , Huang Z , Held C et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012 ; 366 : 20–33.
Kosoglou T , Reyderman L , Tiessen RG et al. Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. Eur J Clin Pharmacol 2012 ; 68 : 249–258.
Zhang P , Gruber A , Kasuda S et al. Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin. Circulation 2012 ; 126 : 83–91.
Gurbel PA , Bliden KP , Turner SE et al. Cell-penetrating pepducin therapy targeting PAR1 in subjects with coronary artery disease. Arterioscler Thromb Vasc Biol 2016 ; 36 : 189–197.
Wong PC, Seiffert D, Bird JE, et al. Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding. Sci Transl Med 2017; 9 : eaaf5294.
Wilson SJ , Ismat FA , Wang Z et al. PAR4 (protease-activated receptor 4) antagonism with BMS-986120 inhibits human ex vivo thrombus formation. Arterioscler Thromb Vasc Biol 2018 ; 38 : 448–456.
Pachel C , Mathes D , Arias-Loza AP et al. Inhibition of platelet GPVI protects against myocardial ischemia-reperfusion injury. Arterioscler Thromb Vasc Biol 2016 ; 36 : 629–635.
Chang CH , Chung CH , Tu YS et al. Trowaglerix venom polypeptides as a novel antithrombotic agent by targeting immunoglobulin-like domains of glycoprotein VI in platelet. Arterioscler Thromb Vasc Biol 2017 ; 37 : 1307–1314.
Voors-Pette C , Lebozec K , Dogterom P et al. Safety and tolerability, pharmacokinetics, and pharmacodynamics of ACT017, an antiplatelet GPVI (glycoprotein VI) Fab: first-in-human healthy volunteer trial. Arterioscler Thromb Vasc Biol 2019 ; 39 : 956–964.
van Eeuwijk JMM , Stegner D , Lamb DJ et al. The novel oral Syk inhibitor, Bl1002494, protects mice from arterial thrombosis and thromboinflammatory brain infarction. Arterioscler Thromb Vasc Biol 2016 ; 36 : 1247–1253.
Piatt R , Paul DS , Lee RH et al. Mice Expressing low levels of CalDAG-GEFI exhibit markedly impaired platelet activation with minor impact on hemostasis. Arterioscler Thromb Vasc Biol 2016 ; 36 : 1838–1846.
Adili R , Tourdot BE , Mast K et al. First selective 12-LOX inhibitor, ML355, impairs thrombus formation and vessel occlusion in vivo with minimal effects on hemostasis. Arterioscler Thromb Vasc Biol 2017 ; 37 : 1828–1839.
Liu Y , Hu M , Luo D et al. Class III PI3K positively regulates platelet activation and thrombosis via PI(3)P-directed function of NADPH oxidase. Arterioscler Thromb Vasc Biol 2017 ; 37 : 2075–2086.
Gremmel T , Yanachkov IB , Yanachkova MI et al. Synergistic inhibition of both P2Y
Dangelmaier C , Manne BK , Liverani E et al. PDK1 selectively phosphorylates Thr(308) on Akt and contributes to human platelet functional responses. Thromb Haemost 2014 ; 111 : 508–517.
Münzer P , Walker-Allgaier B , Geue S et al. PDK1 determines collagen-dependent platelet Ca
Wadanoli M , Sako D , Shaw GD et al. The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time. Thromb Haemost 2007 ; 98 : 397–405.
Jilma-Stohlawetz P , Knöbl P , Gilbert JC et al. The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease. Thromb Haemost 2012 ; 108 : 284–290.
Sathish J , Falati S , Croce K et al. Antibody cross-linking of human platelet P-selectin induces calcium entry by a mechanism dependent upon Fcγ receptor IIA. Thromb Haemost 2004 ; 92 : 598–605.
Tanasescu S , Lkvesque H , Thuillez’ C . Pharmacology of aspirine. Rev Med Interne 2000 ; 21 : suppl 1 s18–s26.
Bennett CL , Connors JM , Carwile JM et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000 ; 342 : 1773–1777.
Schnapf A. . Prasugrel versus clopidogrel: new management strategies for acute coronary syndrome. J Cardiovasc Nurs 2013 ; 28 : 483–494.
Wallentin L , Becker RC , Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009 ; 361 : 1045–1057.
Cada DJ , Baker DE , Ingram KT . Cangrelor. Hosp Pharm 2015 ; 50 : 922–929.
Kim HH , Sawada N , Soydan G et al. Additive effects of statin and dipyridamole on cerebral blood flow and stroke protection. J Cereb Blood Flow Metab 2008 ; 28 : 1285–1293.
DiNicolantonio JJ , Lavie CJ , Fares H et al. Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke. Am J Cardiol 2013 ; 112 : 1230–1234.
Gessler T , Ghofrani HA , Held M et al. The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension. Pulm Circ 2017 ; 7 : 505–513.
De Luca G , Navarese E , Marino P . Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. Eur Heart J 2009 ; 30 : 2705–2713.